Novo Nordisk lands back in Sanders’ crosshairs, this time over steep costs of Ozempic and Wegovy fkansteiner Thu, 04/25/2024 – 14:41 More: Novo Nordisk lands back in Sanders' crosshairs, this time over steep costs of Ozempic and Wegovy Source: fierce
read moreBristol Myers Squibb leans on long-term growth drivers, strategy overhaul to dodge IRA impacts zbecker Thu, 04/25/2024 – 13:05 More: Bristol Myers Squibb leans on long-term growth drivers, strategy overhaul to dodge IRA impacts Source: fierce
read moreSanofi leans on COPD as ‘next major growth pillar’ for its immunology star Dupixent: CEO fkansteiner Thu, 04/25/2024 – 11:32 More: Sanofi leans on COPD as 'next major growth pillar' for its immunology star Dupixent: CEO Source: fierce
read moreMerck CEO Davis dubs Keytruda market exclusivity loss as ‘more of a hill than a cliff’ kdunleavy Thu, 04/25/2024 – 11:14 More: Merck CEO Davis dubs Keytruda market exclusivity loss as 'more of a hill than a cliff' Source: fierce
read moreAstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy aliu Thu, 04/25/2024 – 11:13 More: AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy Source: fierce
read moreX-linked Charcot-Marie-Tooth is the second most common form of the rare peripheral neuropathy disease More: CMT Research Foundation funds study investigating treatment for CMT1X disease Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals